U.S. Markets close in 1 hr 48 mins

Actelion Ltd (ALIOF)


Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
284.30-0.75 (-0.26%)
As of 9:30AM EDT. Market open.
People also watch
ANACAGIOAMAGENTAXLRN

Actelion Ltd

Gewerbestrasse 16
Allschwil 4123
Switzerland
41 61 565 65 65
http://www.actelion.com

Sector
Industry
Full Time Employees2,624

Key Executives

NameTitlePayExercisedAge
Mr. Jean-Paul Clozel M.D.Co-Founder, Chief Exec. Officer and Director5.53MN/A62
Ms. Martine ClozelCo-Founder, Chief Scientific Officer and Sr. VPN/AN/A62
Mr. André C. MullerChief Financial Officer and Exec. Vice-PresN/AN/A54
Mr. Otto SchwarzChief Operating Officer and Exec. VPN/AN/A62
Mr. Andrew C. WeissHead of Investor Relations & Corp. Communications and Sr. VPN/AN/A49
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Actelion Ltd, a biopharmaceutical company, discovers, develops, and commercializes low molecular weight drugs for unmet medical needs. It sells Tracleer, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension (PAH); Opsumit, an orally available endothelin receptor antagonist; and Ventavis, an inhaled formulation of iloprost, a synthetic compound structurally similar to prostacyclin. The company also provides Veletri, an intravenous prostacyclin for the treatment of PAH to enhance exercise capacity; Zavesca, an oral capsule for the treatment of patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option; Valchlor, a topical formulation of mechlorethamine for the treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients; and Uptravi, an oral selective IP receptor agonist targeting the prostacyclin pathway in PAH. Actelion Ltd markets its products in Switzerland, the United States, Europe, Japan, and internationally. The company was founded in 1997 and is headquartered in Allschwil, Switzerland.

Corporate Governance

Actelion Ltd’s ISS Governance QualityScore as of May 1, 2017 is 2. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 1; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.